IMMUNA (IMM01-STEM)
/ Immunis
- LARVOL DELTA
Home
Next
Prev
1 to 11
Of
11
Go to page
1
October 31, 2025
Immunis Publishes Research Showing Body Fat Loss and Reversal of Liver Steatosis and Fibrosis, While Increasing Lean Muscle Mass, in Aged Models
(Businesswire)
- "IMM01-STEM significantly enhanced weight loss in obese mice by reducing the percentage of whole-body fat while increasing lean mass; IMM01-STEM significantly reversed liver steatosis and fibrosis in aged mice on a high fat diet, to levels similar to that of healthy controls; IMM01-STEM provided major metabolic benefits during weight loss, including better glucose tolerance and lower fasting insulin levels, with treated mice achieving metabolic profiles similar to healthy controls; IMM01-STEM preserves muscle mass and enhances muscle quality by increasing muscle fiber size, increasing blood capillary density, and reducing fibrosis."
Preclinical • Obesity
October 31, 2025
STEM-MYO: Safety and Tolerability of IMM01-STEM in Patients With Muscle Atrophy Related to Knee Osteoarthritis.
(clinicaltrials.gov)
- P1/2 | N=28 | Recruiting | Sponsor: Immunis, Inc. | Active, not recruiting ➔ Recruiting | Trial completion date: Dec 2025 ➔ Jun 2026 | Trial primary completion date: Sep 2025 ➔ Mar 2026
Enrollment open • Trial completion date • Trial primary completion date • Immunology • Muscular Atrophy • Osteoarthritis • Pain • Rheumatology
July 01, 2025
Safety and Tolerability of IMM01-STEM in Patients With Muscle Atrophy Related to Knee Osteoarthritis.
(clinicaltrials.gov)
- P1/2 | N=28 | Active, not recruiting | Sponsor: Immunis, Inc. | Completed ➔ Active, not recruiting | N=13 ➔ 28 | Trial completion date: Nov 2024 ➔ Dec 2025 | Trial primary completion date: Aug 2024 ➔ Sep 2025
Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Immunology • Muscular Atrophy • Osteoarthritis • Pain • Rheumatology
March 04, 2025
Immunis’ Treats its First Patients for Sarcopenic Obesity
(Businesswire)
- "Immunis, Inc...announces that it has initiated treatment in several patients of its STEM-META Phase 2 clinical trial. The Phase 2 trial will assess the safety and tolerability of Immunis’ investigational therapy, IMM01-STEM, in older patients with sarcopenia (muscle atrophy) related to obesity."
Trial status • Muscular Atrophy • Obesity
January 30, 2025
Safety and Efficacy of IMM01-STEM Against Placebo on Muscle Performance in Seniors With Obesity and Muscle Weakness
(clinicaltrials.gov)
- P2 | N=55 | Recruiting | Sponsor: Immunis, Inc. | Not yet recruiting ➔ Recruiting
Enrollment open • Genetic Disorders • Obesity • Sarcopenia
January 23, 2025
STEM-META-EAP: INTERMEDIATE-SIZE PATIENT POPULATIONS EXPANDED ACCESS to TREATMENT for SARCOPENIC OBESITY
(clinicaltrials.gov)
- P=N/A | N=0 | Temporarily Not Available | Sponsor: Immunis, Inc.
New trial • Genetic Disorders • Obesity • Sarcopenia
November 08, 2024
Safety and Tolerability of IMM01-STEM in Patients With Muscle Atrophy Related to Knee Osteoarthritis.
(clinicaltrials.gov)
- P1/2 | N=13 | Completed | Sponsor: Immunis, Inc. | Active, not recruiting ➔ Completed | Trial primary completion date: Nov 2024 ➔ Aug 2024
Trial completion • Trial primary completion date • Immunology • Muscular Atrophy • Osteoarthritis • Pain • Rheumatology
September 20, 2024
Safety and Efficacy of IMMUNA Against Placebo on Muscle Performance in Seniors With Obesity and Muscle Weakness
(clinicaltrials.gov)
- P2 | N=55 | Not yet recruiting | Sponsor: Immunis, Inc.
New P2 trial • Genetic Disorders • Obesity • Sarcopenia
September 20, 2024
Safety and Tolerability of IMMUNA(IMM01-STEM) in Patients With Muscle Atrophy Related to Knee Osteoarthritis.
(clinicaltrials.gov)
- P1/2 | N=13 | Active, not recruiting | Sponsor: Immunis, Inc. | Recruiting ➔ Active, not recruiting | Trial primary completion date: Aug 2024 ➔ Nov 2024
Enrollment closed • Trial primary completion date • Immunology • Muscular Atrophy • Osteoarthritis • Pain • Rheumatology
March 05, 2024
Safety and Tolerability of IMMUNA(IMM01-STEM) in Patients With Muscle Atrophy Related to Knee Osteoarthritis.
(clinicaltrials.gov)
- P1/2 | N=18 | Recruiting | Sponsor: Immunis, Inc. | Trial primary completion date: Dec 2023 ➔ Aug 2024
Trial primary completion date • Immunology • Muscular Atrophy • Osteoarthritis • Pain • Rheumatology
February 21, 2023
Safety and Tolerability of IMM01-STEM in Patients With Muscle Atrophy Related to Knee Osteoarthritis.
(clinicaltrials.gov)
- P1/2 | N=18 | Recruiting | Sponsor: Immunis, Inc. | Trial completion date: May 2023 ➔ Sep 2024 | Trial primary completion date: Feb 2023 ➔ Dec 2023
Trial completion date • Trial primary completion date • Immunology • Muscular Atrophy • Osteoarthritis • Pain • Rheumatology
1 to 11
Of
11
Go to page
1